Merck Bio launches proteomics tools
Merck Biosciences has introduced a new range of kits for removing
and extracting protein from complex biological samples used in
Amersham unveils new stain for proteomics
Amersham Biosciences has launched a new stain, called Deep Purple,
which it claims will improve the detection of proteins in 1D and 2D
An agreement between the UK's Procognia and US company Xcellerex
promises to provide a new force in contract manufacturing of
Vitamin to help medicine go down
A partnership between Celltech and Access Pharmaceuticals is
focusing on the use of a vitamin-based delivery technology for
monoclonal antibodies and antibody fragments.
New TOF spectrometer from Waters
Waters has launched a new MALDI-TOF (time of flight) mass
spectrometer, along with a line of porous silicon-coated target
plates and new reference standards,
Hypertension project at Sidec
Sidec Technologies has entered into a contract research
collaboration with a US research institute to study a receptor
involved in the regulation of blood pressure.
Molecular Probes acquisition
Invitrogen completes $325m purchase of Molecular Probes in a deal
which will take the latter's fluorescence labelling technologies
into new markets.
Merck drops Karo Bio compound
The lead compound in Merck and Karo Bio's selective oestrogen
receptor modulator collaboration has been dropped after toxicity
emerged preclinical tests.
Serum stripper aids in biomarker discovery
Agilent launches two new products at the ongoing Drug Discovery
Technology meeting, including an LC column to remove high-abundance
proteins from serum and an oligonucleotide mouse microarray to aid
in toxicogenomics research.
Transgenic production for the birds
US company AviGenics has successfully produced biologically active
human interferon and human monoclonal antibodies in transgenic
GSK signs up for ACLARA's eTag system
GSK is the latest company to sign a license for ACLARA Biosciences'
eTag Assay System, used in gene expression profiling studies.
Amersham comes in low, but on track
Amersham trims its 2003 profit outlook again after reporting lower
interim sales and profits, but points to currency effects and the
underlying strength of the business
Amersham trims 2003 profit forecast again
Amersham trimmed its 2003 profit forecast by £40 million (€57m), or
4.1 pence per share, after reporting lower sales and pre-tax
profits for the first half of 2003.
PIERIS expands IP in Anticalins
PIERIS has strengthened its patent estate for a new class of
proteins which could represent a more flexible alternative to
Amersham alliance on image analysis
Amersham Biosciences and Geneva Bioinformatics have hooked up to
provide a new version of the ImageMaster package used in 2-D gel